Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose intensity for breast cancer.

D K Armstrong1, N E Davidson

  • 1Johns Hopkins Oncology Center, Baltimore, Maryland, USA.

Oncology (Williston Park, N.Y.)
|June 30, 2001
PubMed
Summary

The role of chemotherapy dose intensity in breast cancer treatment is still debated. While higher doses may improve response rates, they don't consistently enhance survival and increase toxicity, questioning routine dose escalation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.

Gynecologic oncology·2019
Same author

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Breast cancer research and treatment·2018
Same author

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Breast Cancer Research

Background:

  • Preclinical data suggest a dose-response relationship for chemotherapy in breast cancer.
  • Substandard chemotherapy dosing is linked to poorer patient outcomes.
  • Increased dose intensity is associated with higher costs and toxicities.

Purpose of the Study:

  • To evaluate the clinical significance of chemotherapy dose intensity in breast cancer.
  • To assess the impact of dose-intensive therapies on treatment outcomes and toxicities.
  • To determine if dose escalation beyond standard regimens is beneficial.

Main Methods:

  • Review of preclinical data and clinical trial results regarding chemotherapy dose intensity.
  • Analysis of response rates, time to progression, and overall survival in breast cancer patients.
  • Examination of toxicities associated with dose-intensive regimens.

Main Results:

  • Increased dose intensity improves response rates in metastatic breast cancer but not consistently overall survival.
  • Dose escalation of alkylating agents and anthracyclines has not shown benefit in the adjuvant setting.
  • Patients with HER2/neu-overexpressing tumors may benefit from dose-intensive therapies.

Conclusions:

  • Conflicting data suggest that routine use of high-dose chemotherapy for breast cancer is not supported outside of clinical trials.
  • Further research is needed to identify specific patient subgroups who may benefit from intensified chemotherapy.
  • The balance between efficacy and toxicity remains a critical consideration in breast cancer treatment intensification.

Related Experiment Videos